Volume 28, Number 2—February 2022
Dispatch
SARS-CoV-2 B.1.619 and B.1.620 Lineages, South Korea, 2021
Ae Kyung Park, Il-Hwan Kim, Heui Man Kim, Hyeokjin Lee, Nam-Joo Lee, Jeong-Ah Kim, SangHee Woo, Chae young Lee, Jaehee Lee, Sae Jin Oh, JeeEun Rhee, Cheon-Kwon Yoo, and Eun-Jin Kim
Table 2
Results from neutralization testing of serum from persons who were infected with and vaccinated against severe acute respiratory syndrome coronavirus 2, South Korea*
| Serum type | PRNT50 GMT (95% CI) |
||
|---|---|---|---|
| G (D614G) | B.1.619 | B.1.620 | |
| Convalescent, n = 7 | 79 (35–179) | 340 (138–830) | 546 (248–1,205) |
| Vaccinated, n = 7 | 32 (16–62) | 76 (37–155) | 584 (303–1,125) |
*Test results against G clade (D614G) and B.1.619 and B.1.620 lineages. GMT, geometric mean titer; PRNT50, 50% plaque reduction neutralization test.
Page created: December 16, 2021
Page updated: January 22, 2022
Page reviewed: January 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.